Icotrokinra

ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

Icotrokinra is a peptide that selectively binds to the IL-23 receptor (IL-23R) with a dissociation constant of 7 pM and antagonizes the binding of IL-23. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Icotrokinra inhibits the IL-23/IL-23R-dependent release of proinflammatory cytokines.

See the full prescribing information for recommended evaluation and immunizations prior to treatment. Recommended dosage is 200 mg orally once daily. Administer ICOTYDE on an empty stomach with water upon waking. Wait at least 30 minutes after taking ICOTYDE before eating food. For patients who have difficulty swallowing tablets, ICOTYDE can be dispersed in water.

None. None.

Infections: Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue ICOTYDE until the infection resolves. Tuberculosis (TB): Consider evaluating for TB prior to initiating treatment with ICOTYDE based on clinical judgment. Monitor patients for signs and symptoms of active TB during and after treatment with ICOTYDE. Immunizations: Avoid use of live vaccines during treatment with ICOTYDE.

Most common adverse reactions (≥1%) are headache, nausea, cough, fungal infection, and fatigue.

Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). Store in original package to protect from moisture.